ASMB
Assembly Biosciences, Inc. NASDAQ Listed Dec 17, 2010$26.74
+10.22%
vs $24.26
Mkt Cap $299.8M
52w Low $17.08
45.1% of range
52w High $38.50
50d MA $26.82
200d MA $28.94
P/E (TTM)
—
EV/EBITDA
—
P/B
1.4x
Debt/Equity
0.0x
ROE
-3.0%
P/FCF
-7.3x
RSI (14)
68.20
ATR (14)
$1.66
Beta
1.16
50d MA
$26.82
200d MA
$28.94
Avg Volume
255.9K
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
331 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.51 | 2.48 | +586.3% | 27.51 | +9.5% | +3.5% | +0.4% | -1.2% | +1.6% | +0.7% | — |
| Nov 10, 2025 | AMC | -0.50 | -0.72 | -44.0% | 32.07 | +0.1% | +3.3% | +8.2% | -0.9% | +3.4% | -1.0% | — |
| Aug 6, 2025 | AMC | -0.65 | -1.33 | -103.6% | 19.43 | -1.5% | +9.2% | +13.0% | -1.5% | +1.7% | +3.2% | — |
| May 8, 2025 | AMC | -2.01 | -1.17 | +41.8% | 11.66 | +2.9% | +5.0% | +0.9% | -0.1% | -1.9% | +3.2% | — |
| Mar 20, 2025 | AMC | -1.75 | -1.57 | +10.3% | 10.69 | +2.9% | +3.0% | +1.0% | +2.7% | -5.3% | +0.8% | — |
| Nov 7, 2024 | AMC | -2.02 | -1.51 | +25.2% | 17.50 | -2.1% | -4.1% | -2.2% | +1.0% | +0.8% | +2.1% | — |
| Aug 8, 2024 | AMC | -2.96 | -1.98 | +33.1% | 13.38 | -6.7% | -2.8% | +0.5% | +14.1% | -6.0% | +0.3% | — |
| May 8, 2024 | AMC | -2.74 | -1.66 | +39.4% | 12.85 | +2.7% | +1.2% | +3.0% | -0.1% | +3.8% | +5.1% | — |
| Mar 27, 2024 | AMC | -2.88 | -2.15 | +25.3% | 13.38 | -1.3% | -0.6% | -3.0% | +4.7% | +2.1% | -1.1% | — |
| Nov 8, 2023 | AMC | -2.76 | -3.24 | -17.4% | 10.20 | +1.2% | -11.8% | +0.0% | -6.7% | -1.4% | +7.2% | — |
| Aug 9, 2023 | AMC | -3.48 | -3.84 | -10.3% | 12.72 | -1.9% | +0.9% | -1.9% | -4.8% | -1.0% | -4.0% | — |
| May 4, 2023 | AMC | -4.44 | -4.44 | +0.0% | 12.48 | -3.8% | -1.0% | +1.0% | +2.9% | +2.8% | -3.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Guggenheim | Maintains | Buy → Buy | — | $29.01 | $29.94 | +3.2% | +0.7% | -2.4% | +2.9% | +1.7% | -4.8% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.67 | $28.65 | -0.1% | +0.7% | -4.1% | -3.8% | +4.2% | +6.1% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.26 | $35.65 | +1.1% | +2.6% | -9.5% | +3.9% | -1.1% | -0.9% |
| Nov 20 | Mizuho | Maintains | Outperform → Outperform | — | $38.00 | $38.77 | +2.0% | -3.3% | +4.8% | -1.5% | -1.3% | -0.6% |
| Oct 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.66 | $27.67 | +0.0% | +2.6% | +0.2% | +2.3% | +1.3% | +4.6% |
| Sep 8 | Guggenheim | Maintains | Buy → Buy | — | $23.82 | $25.05 | +5.2% | -2.1% | -0.7% | -3.8% | +1.5% | -3.3% |
| Mar 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $11.01 | $11.01 | +0.0% | +1.0% | +2.7% | -5.3% | +0.8% | -2.6% |
| Dec 27 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $15.38 | $15.38 | +0.0% | -1.4% | +5.7% | -1.6% | +8.7% | +2.0% |
| Mar 23 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $14.04 | $14.40 | +2.6% | -8.5% | -2.8% | -5.8% | -6.1% | -3.3% |
| Nov 15 | Mizuho | Maintains | Buy → Buy | — | $17.40 | $17.52 | +0.7% | -4.1% | -5.0% | +4.5% | -2.2% | +4.4% |
| Oct 23 | Truist | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Mar 31 | Truist | Maintains | Buy → Buy | — | $24.96 | $25.20 | +1.0% | -1.0% | +0.0% | +2.9% | -1.4% | +5.3% |
| Sep 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $38.76 | $38.64 | -0.3% | +2.2% | -1.2% | -1.8% | +0.6% | +0.3% |
| Sep 1 | William Blair | Downgrade | Outperform → Market Perform | — | $45.60 | $45.72 | +0.3% | +2.6% | -16.2% | -0.3% | -1.8% | -1.2% |
| May 9 | SVB Leerink | Maintains | Market Perform → Market Perform | — | — | — | — | — | — | — | — | — |
| Mar 22 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $58.20 | $58.20 | +0.0% | -3.3% | -5.1% | -2.7% | +3.0% | +0.2% |
| Nov 5 | Jefferies | Downgrade | Buy → Hold | — | $192.48 | $195.12 | +1.4% | -0.9% | -69.4% | +14.4% | -1.6% | -2.4% |
| Oct 19 | Truist | Maintains | Buy → Buy | — | $187.44 | $198.00 | +5.6% | -0.4% | -1.3% | +0.8% | -0.4% | -3.6% |
| Jul 7 | SVB Leerink | Maintains | Outperform → Outperform | — | $276.84 | $274.92 | -0.7% | +3.6% | +1.3% | -2.6% | -2.4% | -0.1% |
| Oct 16 | Mizuho | Maintains | Buy → Buy | — | $111.60 | $126.84 | +13.7% | +36.8% | +21.9% | -3.0% | +0.1% | -6.6% |
| Oct 8 | B. Riley FBR | Upgrade | Neutral → Buy | — | $319.80 | $357.48 | +11.8% | -2.3% | -2.8% | -2.2% | -4.7% | +1.8% |
| Oct 7 | B. Riley Securities | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Aug 8 | Baird | Maintains | Outperform → Outperform | — | $502.44 | $534.48 | +6.4% | +1.8% | -7.1% | -0.1% | -0.0% | -5.6% |
| May 8 | B. Riley FBR | Maintains | Neutral → Neutral | — | $531.36 | $525.24 | -1.2% | -7.3% | +2.3% | -4.7% | +1.5% | +3.7% |
| May 7 | B. Riley Securities | Maintains | Neutral → Neutral | — | $539.04 | $538.56 | -0.1% | -1.4% | -7.3% | +2.3% | -4.7% | +1.5% |
| Apr 12 | Chardan Capital | Downgrade | Buy → Neutral | — | $603.48 | $603.60 | +0.0% | -3.4% | -7.7% | +0.2% | +5.9% | -2.0% |
| Jan 5 | B. Riley FBR | Maintains | Neutral → Neutral | — | $538.92 | $538.80 | -0.0% | -4.0% | -3.3% | +0.1% | +5.4% | +1.5% |
| Nov 8 | Jefferies | Maintains | Buy → Buy | — | $389.04 | $394.56 | +1.4% | +8.4% | +0.0% | -3.8% | -1.4% | -0.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Bjorkquist Jeanette M | PFO and PAO | Sell | 29 | $23.25 | $674 | 14,560 | +2.91% | +10.22% |
8-K · 8.01
!! High
Assembly Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
May 26
8-K · 8.01
!! High
Assembly Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
May 22
8-K · 2.02
!! High
Assembly Biosciences, Inc. -- 8-K 2.02: Earnings Results
Assembly Biosciences reported quarterly earnings results; investors should review the attached press release for specific financial performance metrics and guidance updates affecting the ASMB and GILD stock valuations.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
ASMB's new executive compensation structure ties pay to specific departmental and company-wide performance metrics, signaling management expects accountability for results and may improve operational efficiency.
Mar 30
8-K
Unknown — 8-K Filing
Assembly Biosciences' optimistic 2025 guidance and pivot toward viral disease therapeutics could drive share appreciation if pipeline candidates advance, but investors should verify clinical progress claims against actual trial data.
Mar 19
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Virtus LifeSci Biotech Clinical Trials ETF | 7,804 | $201K | Jan 2026 |
| 2 | Avantis U.S. Small Cap Equity ETF | 6,096 | $182K | Feb 2026 |
| 3 | Small Cap Core Fund | 4,966 | $138K | Mar 2026 |
| 4 | Avantis U.S. Small Cap Equity Fund | 1,166 | $35K | Feb 2026 |
Valuation
Market Cap
$299.8M
Enterprise Value
$51.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.68x
P/B
1.45x
P/S
4.22x
P/FCF
-7.28x
EV/EBITDA
—
Shares Out
11.2M
Financials (TTM)
Revenue
$71.1M
Net Income
-$6.4M
EBITDA
-$6.3M
Free Cash Flow
-$41.2M
Op Cash Flow
-$41.1M
EPS Basic
$-0.55
EPS Diluted
$-0.58
EPS Forward
$-1.96
Gross Margin
77.2%
Op Margin
-19.1%
Net Margin
-9.0%
Balance Sheet
Total Assets
$257.6M
Total Liab.
$50.8M
Total Equity
$206.8M
Cash
$248.1M
LT Debt
$0
Book Value/Sh
$18.44
Debt/Equity
0.01x
Current Ratio
5.22
Quick Ratio
5.22
Returns & Growth
ROE
-3.0%
ROA
-2.4%
ROIC
-5.8%
Rev Growth YoY
+153.5%
EPS Growth YoY
+91.8%
Price Returns
2W
-8.7%
1M
+2.6%
3M
-7.3%
6M
-26.8%
12M
+95.5%
Technicals
52W High
$38.50
52W Low
$17.08
50d MA
$26.82
200d MA
$28.94
RSI (14)
68.20
ATR (14)
$1.66
Beta
1.16
Avg Volume
256K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$40.00
High
$40.00
Low
$40.00
Median
$40.00
Data updated apr 24, 2026 7:15pm
· Source: financialmodelingprep.com